Agenda

Programme

Friday: September 6, 2019

17.30 - 18.00

Opening Address Special Lecture; Jay Bradner
President of the Novartis Institutes for BioMedical Research (NIBR)

18.00 - 20.00

Welcome Reception

Saturday: September 7, 2019

07.30 - 08.00

Breakfast

07.45

Meeting Registration

08.00

Introduction & Meeting Objectives
John Gribben

08.15 - 09.45

Session I: T-cell Lymphomas

Chairs: Laurence de Leval & Francine Foss

  • Defining vulnerabilities and new targets in peripheral T-cell lymphomas; David Weinstock
  • TCR signalling pathway in T-cell lymphomas pathogenesis and implications for therapy; Roberto Chiarle
  • Indications of brentuximab vedotin and stem cell transplantation in the management of T-cell lymphomas; Ranjana Advani
  • Identification of patients with HTLV1 infection at high risk for progression to ATLL; Lucy Cook


Roundtable Discussion: 
Laurence de Leval, Francine Foss & Session Speakers

09.45 - 10.30

Special Lecture: 25 years after REAL: Looking back and looking forward

Chairs: John Gribben & Laurence de Leval

  • Elaine Jaffe

10.30 - 10.45

Coffee Break

10.45 - 12.45

Session II: The Tumor Microenvironment in Lymphoma

Chairs: Nathan Fowler 

  • Genetics of follicular lymphoma and their impact on the tumor microenvironment; Robert Kridel
  • Novel therapies targeting the microenvironment; Nathan Fowler
  • Optimizing checkpoint inhibitors; TBC
  • Immunomodulatory drugs and the immune microenvironment; TBC


Roundtable Discussion

12.45 - 13.45

Lunch

13.45 - 14.45

Session III: Keynote Address & Special Topic

Chairs: John Gribben

  • Genetic bases of immune evasion in lymphoid malignancies; Margaret Shipp


Roundtable Discussion

14.45 - 16.45

Session IV: Immunotherapy of Lymphoma

Chairs: Laurie Sehn & Ranjana Advani

  • Targeting lymphocyte checkpoints in NHL; Kerry Savage
  • Targeting the macrophage checkpoint in NHL; Ranjana Advani
  • Bi-specific antibodies in NHL; Laurie Sehn
  • How do we rationally combine immunotherapy approaches and design clinical trials?; Philippe Armand
  • Pharmacodynamic markers of immunotherapy approaches – how can we measure benefit?; John Gribben


Roundtable Discussion:
 Session Speakers

19.00

17th iwNHL Dinner

Sunday: September 8, 2019

08.00 - 09.00

Breakfast

09.00 - 11.00

Session V: Novel Lymphoma Targets/Agents

Chairs: John Gribben & Tom Witzig

  • Venetoclax combinations in DLBCL; Sven De Vos
  • SYK-JAK inhibitors; Certulatinib update; TBC
  • ADC (Polatuzumab) combinations in DLBCL; Laurie Sehn
  • Oral PI3K delta (δ) inhibitors in lymphoma; Sven de Vos
  • Ibrutinib combinations for NHL; Francisco Hernandez-Illizariturri
  • 2nd generation novel BTK inhibitors in lymphoma:
    • Zanubrutinib; Constantine Tam 
    • Acalabrutinib in R/R MCL; Tom Witzig
  • SINE inhibitors: Selinexor; Tom Witzig


Roundtable Discussion: 
Session Speakers

11.00 - 11.15

Coffee Break

11.15 - 13.30

Session VI: T-Cell Therapies for Lymphoma – CD19-CARs and Beyond

Chairs: Cath Bollard & Dave Maloney

  • CD19-CAR-T overview; Dave Maloney
  • Factors impacting PFS after CD19 CAR-T cells; Cameron Turtle
  • CD20-CAR-T therapy for NHL; Brian Till 
  • CD5 and CD7 CAR-T cells; Max Mamonkin
  • CD30 CAR-T cells; Barbara Savoldo
  • TAA-specific T cells; Cath Bollard


Roundtable Discussion

13.30 - 13.45

Final Meeting Summary & Conclusions
iwNHL Committee

13.45 - 14.30

Closing Lunch

map pin

Location

Royal Sonesta Boston Hotel
40 Edwin H Land Boulevard,
Cambridge, MA, USA

© 2014 - 2019 World Health Communications Ltd

Media Partner:

Meeting Organizers: